Abstract: In recent years, carbapenem-resistant Enterobacteria have been increasing, and the variety of clinical treatment drugs is limited, and the mortality rate is high. In vitro experiments have shown that carbapenemase has a significantly higher affinity for ertapenem than other carbapenem varieties, so it can consume carbapenemase and prevent the decomposition of other carbapenem varieties. Therefore, ertapenem is combined with other carbapenems to treat carbapenem-resistant Enterobacteria. This article reviews the mechanism, clinical efficacy and influencing factors of the double carbapene regimen, and provides reference and guidance for the clinical treatment of carbapenem-resistant Enterobacteria.